Browsing by Author "Nikolaides, C."
Now showing items 1-20 of 33
-
Article
Anthracycline-based chemotherapy of primary non-Hodgkin's lymphoma of the testis: The Hellenic Cooperative Oncology Group experience
Pectasides, Dimitrios; Economopoulos, T.; Kouvatseas, G.; Antoniou, A.; Zoumbos, Z.; Aravantinos, Gerasimos; Tsatalas, C.; Halikia, A.; Nikolaides, C.; Kiamouris, Ch; Pappa, E.; Pavlidis, Nicholas; Skarlos, Dimosthenis V.; Fountzilas, George; Dimopoulos, M. A. (2000)Testicular non-Hodgkin's lymphoma is an uncommon disease and its outcome following chemotherapy and/or radiotherapy has been variable. A retrospective analysis was performed on 26 patients with primary testicular lymphoma ...
-
Article
Are the effects of tamoxifen on the serum lipid profile modified by apolipoprotein E phenotypes?
Liberopoulos, E. N.; Karabina, S. A.; Tselepis, A.; Bairaktari, Eleni Th; Nikolaides, C.; Pavlidis, Nicholas; Elisaf, Moses S. (2002)Background: Tamoxifen has favorable effects on the serum lipid profile. It has been suggested that the apolipoprotein (Apo) E phenotype can influence serum lipid parameters; the ApoE allele 4 (ApoE4) is associated with ...
-
Article
Bcl2 and p53 protein expression in metastatic carcinoma of unknown primary origin: Biological and clinical implications. A Hellenic co-operative oncology group study
Briassoulis, E. Ch; Tsokos, M.; Fountzilas, George; Bafaloukos, Dimitrios; Kosmidis, Paraskevas A.; Samantas, E.; Skarlos, Dimosthenis V.; Nikolaides, C.; Pavlidis, Nicholas (1998)We have previously shown that metastatic carcinomas of unknown primary site overexpress several tumor markers as well as the products of the oncogenes c-myc, ras and c-erbB2. We analysed the tissue expression of the protein ...
-
Article
The beneficial effect of tamoxifen on serum lipoprotein-a levels: An additional anti-atherogenic property
Elisaf, Moses S.; Bairaktari, Eleni Th; Nikolaides, C.; Fountzilas, George; Tzallas, C. S.; Siamopoulos, K. C.; Tsolas, O.; Pavlidis, Nicholas (1996)It has recently been suggested that increased lipoprotein (a) levels are an independent risk factor for coronary heart disease. It has also been reported that tamoxifen can induce changes in blood lipid values. In this ...
-
Article
CEOP-21 versus CEOP-14 chemotherapy with or without rituximab for the first-line treatment of patients with aggressive lymphomas: Results of the HE22A99 trial of the hellenic cooperative oncology group
Economopoulos, T.; Psyrri, A.; Dimopoulos, M. A.; Kalogera-Fountzila, Anna; Pavlidis, Nicholas; Tsatalas, C.; Nikolaides, C.; Mellou, S.; Xiros, N.; Fountzilas, George (2007)Background: In this study we investigated whether administering CEOP (cyclophosphamide, epirubicin, vincristine [Oncovin], and prednisone) every 2 weeks (CEOP-14) instead of every 3 weeks (the standard CEOP-21 regimen) ...
-
Article
Clinical value of CA 15-3, mucin-like carcinoma-associated antigen, tumor polypeptide antigen, and carcinoembryonic antigen in monitoring early breast cancer patients
Pectasides, Dimitrios; Pavlidis, Nicholas; Gogou, L.; Antoniou, F.; Nikolaides, C.; Tsikalakis, D.; Fountzilas, George (1996)A total of 209 postsurgical breast cancer patients were prospectively monitored with simultaneous serum level estimations of CA 15-3, mucin-like carcinoma-associated antigen (MCA), tumor polypeptide antigen (TPA), and ...
-
Article
Diffuse large cell lymphomas: Identification of prognostic factors and validation of the international non-Hodgkin's Lymphoma Prognostic Index
Nikolaides, C.; Fountzilas, George; Zoumbos, N.; Skarlos, Dimosthenis V.; Kosmidis, Paraskevas A.; Pectasides, Dimitrios; Karabelis, A.; Giannakakis, T.; Symeonidis, A.; Papadopoulos, A.; Antoniou, F.; Pavlidis, Nicholas (1998)Several clinical prognostic factors have been identified that predict treatment outcome in patients with diffuse large cell lymphomas. An International Non-Hodgkin's Lymphoma Prognostic Index (IPI) has been recently ...
-
Article
Do LH-RH analogues induce effects similar to tamoxifen on serum lipid parameters in premenopausal women with breast cancer? A prospective study
Elisaf, Moses S.; Bairaktari, Eleni Th; Nikolaides, C.; Fountzilas, George; Tzallas, C. S.; Tsolas, O.; Siamopoulos, K. C.; Pavlidis, Nicholas (1998)Background and Aim: As a continuation of our investigational program we carried out the present study to evaluate and compare the impact of LH-RH analogues and tamoxifen on serum lipid parameters in premenopausal women ...
-
Article
Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: A hellenic cooperative oncology group phase II study
Fountzilas, George; Nikolaides, C.; Bafaloukos, Dimitrios; Kalogera-Fountzila, Anna; Kalofonos, H. P.; Samelis, G.; Aravantinos, Gerasimos; Pavlidis, Nicholas (2000)A phase II study was conducted to evaluate the activity and toxicity profile of the combination of docetaxel and gemcitabine in anthracycline- resistant advanced breast cancer (ABC). Thirty-nine eligible patients with a ...
-
Article
Dose-dense adjuvant chemotherapy with epirubicin monotherapy in patients with operable breast cancer and ≥ 10 positive axillary lymph nodes
Fountzilas, George; Nikolaides, C.; Aravantinos, Gerasimos; Skarlos, Dimosthenis V.; Kosmidis, Paraskevas A.; Papakostas, P.; Stathopoulos, G. P.; Kontostolis, E.; Bafaloukos, Dimitrios; Pavlidis, Nicholas (1998)Forty-one patients with operable breast cancer and ≥ 10 positive axillary lymph nodes were treated with 6 cycles of dose-dense adjuvant chemotherapy consisting of epirubicin (100 mg/m2) every 2 weeks with G-CSF support. A ...
-
Article
Dose-dense sequential adjuvant chemotherapy with epirubicin, paclitaxel and CMF in high-risk breast cancer
Fountzilas, George; Papadimitriou, C.; Aravantinos, Gerasimos; Nikolaides, C.; Stathopoulos, G. P.; Bafaloukos, Dimitrios; Kalofonos, H. P.; Economopoulos, T.; Skarlos, Dimosthenis V.; Pavlidis, Nicholas; Dimopoulos, M. A. (2001)Dose-dense sequential chemotherapy appears to be a promising approach in the management of patients with operable breast cancer. We evaluated the tolerability of such a novel chemotherapeutic regimen in high-risk patients. ...
-
Article
Effect of letrozole on the lipid profile in postmenopausal women with breast cancer
Elisaf, Moses S.; Bairaktari, Eleni Th; Nikolaides, C.; Kakaidi, B.; Tzallas, C. S.; Katsaraki, A.; Pavlidis, Nicholas (2001)Hormonal therapy plays a central role in the overall treatment of breast cancer. Aromatase inhibitors can inhibit the aromatase enzyme system resulting in a reduction of oestrogens. Letrozole is a non-steroidal aromatase ...
-
Article
First-line chemotherapy with paclitaxel by three-hour infusion and carboplatin in advanced breast cancer (final report): A phase II study conducted by the Hellenic Cooperative Oncology Group
Fountzilas, George; Dimopoulos, M. A.; Papadimitriou, C.; Kalogera-Fountzila, Anna; Aravantinos, Gerasimos; Bafaloukos, Dimitrios; Athanasiades, A.; Nikolaides, C.; Keramopoulos, A.; Pavlidis, Nicholas; Kosmidis, Paraskevas A.; Skarlos, Dimosthenis V. (1998)Purpose: To evaluate the activity and toxicity of the combination of paclitaxel given by three-hour infusion, and carboplatin as first- line chemotherapy in patients with advanced breast cancer (ABC). Background: Paclitaxel ...
-
Article
Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: A phase II study conducted by the Hellenic Cooperative Oncology Group
Nikolaides, C.; Dimopoulos, M. A.; Samantas, E.; Bafaloukos, Dimitrios; Kalofonos, H. P.; Fountzilas, George; Razi, E. D.; Kosmidis, Paraskevas A.; Pavlidis, Nicholas (2000)Background: Gemcitabine and vinorelbine have shown activity in breast cancer. A phase II trial was initiated in order to evaluate the response rate (RR) and time to progression (TTP) of the combination of the two drugs in ...
-
Article
High levels of topoisomerase IIα protein expression in diffuse large B-cell lymphoma are associated with high proliferation, germinal center immunophenotype, and response to treatment
Pentheroudakis, George; Goussia, Anna; Voulgaris, E.; Nikolaides, C.; Ioannidou, E.; Papoudou-Bai, A.; Grepi, K.; Kanavaros, P.; Pavlidis, Nicholas; Bai, M. C. (2010)Gene copy number and protein expression of topoisomerase IIα were correlated to benefit from anthracyclines in various tumors. A retrospective series of 69 patients with DLBCL managed with CHOP chemotherapy were studied ...
-
Article
Intensified carboplatin regimen with GM-CSF support in non-small cell lung cancer (NSCLC). A Hellenic Co-operative Oncology Group study (HeCOG)
Nikolaides, C.; Klouvas, G. D.; Fountzilas, George; Athanasiades, A.; Skarlos, Dimosthenis V.; Samantas, E.; Kosmidis, Paraskevas A.; Mylonakis, N.; Pavlidis, Nicholas (1997)This is a continuation of a HeCOG previous trial utilizing carboplatin and vindesine in conventional doses as a non-toxic regimen provided easily on an outpatient basis in NSCLC. In the present study we investigated whether ...
-
Article
Is the combination of 5-fluorouracil and folinic acid effective in advanced gastric carcinoma? Results of a pilot study and review of the literature
Pavlidis, Nicholas; Nikolaides, C.; Klouvas, G. D.; Briassoulis, E. Ch (1994)The main purpose of this trial was to investigate the activity of a less toxic regimen in patients with advanced gastric carcinoma regarding response rate and survival. We report on a pilot study of 20 patients treated ...
-
Article
Low expression of p27 protein combined with altered p53 and Rb/p16 expression status is associated with increased expression of cyclin A and cyclin B1 in diffuse large B-cell lymphomas
Bai, M. C.; Vlachonikolis, J.; Agnantis, Niki J.; Tsanou, E.; Dimou, S.; Nikolaides, C.; Stefanaki, S. V.; Pavlidis, Nicholas; Kanavaros, P. (2001)The expression of the cyclin-dependent kinase inhibitor (CDKI) p27 protein was investigated in relation to (1) the expression of the cell cycle regulators p53, Rb and p16 and (2) the proliferation profile as determined by ...
-
Article
Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): A multicenter randomized trial
Kosmidis, Paraskevas A.; Mylonakis, N.; Skarlos, Dimosthenis V.; Samantas, E.; Dimopoulos, M. A.; Papadimitriou, C.; Kalofonos, H. P.; Pavlidis, Nicholas; Nikolaides, C.; Papaconstantinou, C.; Fountzilas, George (2000)Purpose: The combination of paclitaxel and carboplatin has become a widely used regimen in NSCLC due to phase II reports of moderate toxicity, reasonable activity and easy outpatient administration. Purpose of our present ...
-
Article
Paclitaxel and gemcitabine in advanced non-nasopharyngeal head and neck cancer: A phase II study conducted by the Hellenic Cooperative Oncology Group
Fountzilas, George; Stathopoulos, G. P.; Nikolaides, C.; Kalogera-Fountzila, Anna; Kalofonos, H. P.; Nikolaou, A.; Bacoyiannis, Charalambos; Samantas, E.; Papadimitriou, C.; Kosmidis, Paraskevas A.; Daniilidis, J.; Pavlidis, Nicholas (1999)Background: Paclitaxel as monotherapy or in combination with other drugs has demonstrated significant activity in patients with squamous cell carcinoma of the head and neck region (SCCHN). Preclinical studies have shown ...